Banner

Banner Health Enhances Surgical Efficiencies with the Qventus Perioperative Solution

Retrieved on: 
星期一, 四月 15, 2024
Technology, Surgery, Hospitals, Other Technology, Software, Managed Care, Health, General Health, Artificial Intelligence, Ecosystem, AUC, Hospital, Banner Health, AI, Machine learning, EHR, Electronic health record, Partnership, KLAS, Automation, Data, Synthetic media, Banner, Patient, Generative, Nursing

Qventus, Inc. announced today that Banner Health, one of the largest non-profit health systems in the country, has chosen the Qventus Perioperative Solution to maximize operating room access, increase strategic case growth, and provide actionable, real-time insights.

Key Points: 
  • Qventus, Inc. announced today that Banner Health, one of the largest non-profit health systems in the country, has chosen the Qventus Perioperative Solution to maximize operating room access, increase strategic case growth, and provide actionable, real-time insights.
  • Due to initial success and double-digit return on investment, Banner is currently in the process of expanding the use of the Qventus Perioperative Solution enterprise-wide.
  • “Surgical demand is on the rise,” said Dr. Nirav Patel, Medical Director, Surgical and Procedural Services, Banner Health.
  • By implementing the Qventus Perioperative Solution, Banner Health has taken a significant step forward in enhancing surgical efficiencies and ultimately improving patient and staff experiences.

Newsweek Again Names Banner Bank One of the Most Trustworthy Companies in America

Retrieved on: 
星期一, 四月 15, 2024
Banking, Professional Services, Finance, Statista, Multimedia, Trust (social science), Banner, Banner Bank, Trust

Newsweek has selected Banner Bank as one of America’s Most Trustworthy Companies 2024, ranking Banner 3rd among the 27 banks and credit unions that made the cut.

Key Points: 
  • Newsweek has selected Banner Bank as one of America’s Most Trustworthy Companies 2024, ranking Banner 3rd among the 27 banks and credit unions that made the cut.
  • This prestigious list is compiled by Newsweek, in collaboration with market research partner Statista Inc., the world-leading statistics portal and industry ranking provider.
  • From that, Newsweek and Statista teams selected the 700 most trustworthy companies across 23 industries.
  • Last year, Newsweek selected Banner for the same recognition as well as one of the World’s Most Trustworthy Companies.

Medaptus and Banner Health Partner to Revolutionize Charge Processing with Charge Pro: Beyond Automation to Enhanced Efficiency and Precision

Retrieved on: 
星期三, 四月 24, 2024
Hospital, Banner, Partnership, Patient, Hospital medicine, Banner Health

Before Charge Pro, Banner Health was manually reconciling charges across multiple facilities.

Key Points: 
  • Before Charge Pro, Banner Health was manually reconciling charges across multiple facilities.
  • With Charge Pro, Banner can improve their revenue integrity by reducing the number of missing charges.
  • By leveraging Charge Pro beyond charge reconciliation, we are pioneering a new era of precision and effectiveness in healthcare administration, " said Lou Ellen Parsons, Director, Hospital Medicine at Banner Medical Group.
  • "Professional charge reconciliation has been the core of what Medaptus has been solving for over 20 years.

Ellucian Leads Higher Education's Digital Transformation with Banner and Colleague SaaS

Retrieved on: 
星期一, 四月 8, 2024
Software as a service, University, Saint John's University, Education, SAN, ERP, Software, Faculty, Student, Banner, Management

SAN ANTONIO and RESTON, Va., April 8, 2024 /PRNewswire/ -- Ellucian, the leading higher education technology solutions provider, has established itself as the unmatched Software as a Service (SaaS) leader in higher education, as it continues to accelerate transformation of the industry. More than 2,000 institutions serving 15 million+ students around the globe are leveraging Ellucian SaaS solutions. And in 2023 alone, there were 79 Ellucian SaaS ERP/SIS selections by colleges, universities and university systems, further solidifying the company's position as the preferred choice for institutions. With more than 50 years of experience exclusively serving colleges and universities, Ellucian has the expertise to deliver innovative and reliable SaaS solutions such as Banner and Colleague, designed with the agility to meet and exceed the unique and evolving needs of higher education.

Key Points: 
  • More than 2,000 institutions serving 15 million+ students around the globe are leveraging Ellucian SaaS solutions.
  • And in 2023 alone, there were 79 Ellucian SaaS ERP/SIS selections by colleges, universities and university systems, further solidifying the company's position as the preferred choice for institutions.
  • With more than 50 years of experience exclusively serving colleges and universities, Ellucian has the expertise to deliver innovative and reliable SaaS solutions such as Banner and Colleague, designed with the agility to meet and exceed the unique and evolving needs of higher education.
  • Ellucian serves 2,900 customers in 50 countries with more than 2,000 institutions leveraging SaaS solutions.

Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

Retrieved on: 
星期三, 三月 13, 2024
Research, Gene silencing, George Washington, Phio Pharmaceuticals, Skin cancer, George Washington University, Merkel-cell carcinoma, Patient, Associate, Clinical trial, Safety, Banner, Melanoma, PD-1

Banner MD Anderson Cancer Center in Gilbert, Arizona

Key Points: 
  • Banner MD Anderson Cancer Center in Gilbert, Arizona
    Integrity Research Clinical Associates in Delray Beach, Florida
    These sites join Centricity Research in Dublin, Ohio, which enrolled the study’s first patient in November.
  • The principal investigator at the George Washington University trial is Vishal Patel, M.D.
  • at the Banner MD Anderson Cancer Center trial site.
  • More information about this clinical trial is available at clinicaltrials.gov (identifier: NCT06014086 ).

Ludi, Inc. Appoints Chief Commercial Officer and VP of Provider Compensation

Retrieved on: 
星期二, 四月 2, 2024
Software, Practice Management, Human Resources, Health, Hospitals, Health Technology, Professional Services, Technology, Principal, Negotiation, Software as a service, Information technology, Chlorophyll, GenesisCare, KLAS, Sunquest Information Systems, Knowledge, Banner Health, Banner, Motorola, Fair market value, Multimedia, Information system, Arena, PSAS, Management

Nashville-based Ludi, Inc., the leader in provider compensation management, today announces the appointment of Tom Arena as Chief Commercial Officer and Eric Leafgreen as Vice President of Provider Compensation.

Key Points: 
  • Nashville-based Ludi, Inc., the leader in provider compensation management, today announces the appointment of Tom Arena as Chief Commercial Officer and Eric Leafgreen as Vice President of Provider Compensation.
  • Leafgreen has nearly two decades of experience leading financial operations, provider integration and managing enterprise risk with provider arrangements.
  • He comes to Ludi from GenesisCare, an integrated oncology and multi-specialty provider network, where he was responsible for developing and negotiating provider compensation models.
  • Additionally, he advised on compensation plans, provider practice acquisitions and overall provider payment practices.

Regard and Banner Health Expand Partnership to Bring Clinical Automation to More Hospitals

Retrieved on: 
星期一, 三月 18, 2024
Intelligence, Banner, Partnership, LOS, Diagnosis, EHR, EMR, Patient, Face, Banner Health, Health, Communication, CDI

LOS ANGELES, March 18, 2024 /PRNewswire/ -- Regard, an AI clinical platform within the EHR that helps clinicians diagnose medical conditions, today announced an expanded enterprise-wide partnership with Banner Health, one of the country's largest nonprofit health systems. Banner will roll out Regard's tool in a phased approach to all 33 acute-care hospitals spanning six states in the system in 2024.

Key Points: 
  • Banner will roll out Regard's tool in a phased approach to all 33 acute-care hospitals spanning six states in the system in 2024.
  • Regard and Banner originally partnered in June of 2022 with a pilot at Banner Thunderbird Medical Center.
  • Recognizing successful adoption and performance of the pilot, Banner will implement the company's clinical automation technology.
  • Regard uses proprietary algorithms and artificial intelligence to generate clinical insights to improve workflows and patient care.

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMT

Retrieved on: 
星期一, 二月 26, 2024
Actinium, Leukemia, AML, TCT, Physician, Banner, TP53, BMT, Hematology, Society, Patient, Nuclear medicine, Survival, Transplant, Acute myeloid leukemia

NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported new analyses from the positive Phase 3 SIERRA trial of Iomab-B in oral presentations at the at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT® (American Society for Transplantation and Cellular Therapy and CIBMTR®  (Center for International Blood and Marrow Transplant Research). The presentations reported unprecedented 100% access to potentially curative bone marrow transplant (BMT) and engraftment in evaluable patients with active relapsed or refractory acute myeloid leukemia (r/r AML) and improved long-term survival outcomes greater than 2 years in patients age 65 or older. Patients with r/r AML age 65 and older who also have multiple comorbidities and high-risk cytogenetics have a poor prognosis are seldom offered BMT in current practice due to poor tolerance to induction and conditioning regimens and dismal outcomes. The SIERRA results presented at TCT demonstrate Iomab-B's ability to overcome multiple high-risk features including a TP53 genetic mutation, advanced age and treatment resistant disease. The two oral presentations at this year's TCT mark a total of ten oral presentations of the SIERRA results at various leading transplant, hematology and nuclear medicine conferences in the USA and Europe.

Key Points: 
  • The SIERRA results presented at TCT demonstrate Iomab-B's ability to overcome multiple high-risk features including a TP53 genetic mutation, advanced age and treatment resistant disease.
  • Patients receiving Iomab-B had significantly higher rates of complete remission as well as durable complete remission compared to the control arm.
  • Most importantly, Iomab-B produced improved long-term survival outcomes as only the patients receiving Iomab-B achieved 1-year and 2-year survival.
  • Iomab-B represents an important advancement in transplant conditioning and has the potential to address a significant unmet patient need."

Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)

Retrieved on: 
星期二, 十二月 12, 2023
Therapeutic index, Associate, MTD, Oncology, Symantec Endpoint Protection, Index, Banner, FDA, Cytokine release syndrome, Hematology, BCMA, Incidence, SAN, Society, Therapy, Publication, Lymphoma, ASH, CRS, RRMM, Patient, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported data from the Phase 1 study of HPN217 in patients with RRMM in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. Harpoon also announced the selection of 12 mg as the HPN217 RP2D.

Key Points: 
  • Harpoon also announced the selection of 12 mg as the HPN217 RP2D.
  • During the trial, 97 patients with RRMM who had received at least three prior therapies were enrolled across 15 dose escalation cohorts and three expansion regimens.
  • As of the data cut-off of October 17, 2023, the data demonstrated:
    Clinical activity across a wide dose range (2.15 mg to 24 mg).
  • The maximum tolerated dose (MTD) was not reached at the target dose using a step up approach.

THE BALTIMORE BANNER SELECTS BOB COHN AS CHIEF EXECUTIVE OFFICER

Retrieved on: 
星期二, 十二月 19, 2023
Report, Economist, Yale Law School, Capital Area Food Bank, Cohn, Publishing, Adweek, Banner, Journalism, News, Stanford University, Baltimore Banner, Boston University, Wired, Growth, Institute of Politics, The Atlantic, Newsweek, Harvard University, Management

BALTIMORE, Dec. 19, 2023 /PRNewswire/ -- The Baltimore Banner today announced Bob Cohn has been named Chief Executive Officer ("CEO") of the local nonprofit news organization as it approaches its second anniversary. Cohn replaces Imtiaz Patel, who left The Banner in July.

Key Points: 
  • BALTIMORE, Dec. 19, 2023 /PRNewswire/ -- The Baltimore Banner today announced Bob Cohn has been named Chief Executive Officer ("CEO") of the local nonprofit news organization as it approaches its second anniversary.
  • Cohn replaces Imtiaz Patel, who left The Banner in July.
  • "On behalf of our board of directors and our incredible staff, I'm thrilled to welcome Bob Cohn to The Venetoulis Institute and The Baltimore Banner as our new Chief Executive Officer," said Stewart Bainum, Chairman of the Board.
  • "The Banner has already emerged as an indispensable source for local news in Baltimore and surrounding Maryland, and I look forward to leading its next phase of growth," said Bob Cohn.